Equity Overview
Price & Market Data
Price: $1.09
Daily Change: -$0.015 / 1.38%
Range: $1.06 - $1.13
Market Cap: $65,722,140
Volume: 122,344
Performance Metrics
1 Week: 19.89%
1 Month: -6.90%
3 Months: -34.55%
6 Months: -61.43%
1 Year: -65.82%
YTD: -37.21%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.